MacroGenics (NASDAQ:MGNX) Releases Earnings Results, Misses Expectations By $0.02 EPS

MacroGenics (NASDAQ:MGNX) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.02), Zacks reports. The business had revenue of $49.40 million during the quarter, compared to analysts’ expectations of $34.17 million. MacroGenics had a negative net margin of 69.07% and a negative return on equity of 89.42%.

MacroGenics Stock Performance

MacroGenics stock traded down $0.14 during trading on Friday, reaching $1.97. The company had a trading volume of 186,013 shares, compared to its average volume of 1,152,013. The firm’s 50-day simple moving average is $2.68 and its 200 day simple moving average is $3.23. The firm has a market capitalization of $123.33 million, a PE ratio of -1.27 and a beta of 2.12. MacroGenics has a 1-year low of $1.97 and a 1-year high of $19.54.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.